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Background: Various metrics of hospital antibiotic use might assist in guiding antimicrobial stewardship (AMS).
Objectives: To compare patient outcomes in association with three methods to measure and feedback informa-
tion on hospital antibiotic use when used in developing an AMS intervention.
Methods: Three methods were randomly allocated to 42 clusters from 21 Dutch hospitals: (1) feedback on
quantity of antibiotic use [DDD, days-of-therapy (DOT) from hospital pharmacy data], versus feedback on (2)
validated, or (3) non-validated quality indicators from point prevalence studies. Using this feedback together
with an implementation tool, stewardship teams systematically developed and performed improvement strat-
egies. The hospital length of stay (LOS) was the primary outcome and secondary outcomes included DOT, ICU
stay and hospital mortality. Data were collected before (February–May 2015) and after (February–May 2017) the
intervention period.
Results: The geometric mean hospital LOS decreased from 9.5 days (95% CI 8.9–10.1, 4245 patients) at baseline
to 9.0 days (95% CI 8.5–9.6, 4195 patients) after intervention (P < 0.001). No differences in effect on LOS or
secondary outcomes were found between methods. Feedback on quality of antibiotic use was used more often
to identify improvement targets and was preferred over feedback on quantity of use. Consistent use of the im-
plementation tool seemed to increase effectiveness of the AMS intervention.
Conclusions: The decrease in LOS versus baseline likely reflects improvement in the quality of antibiotic use with
the stewardship intervention. While the outcomes with the three methods were otherwise similar, stewardship
teams preferred data on the quality over the quantity of antibiotic use.
Introduction
To curb antimicrobial resistance, better use of antibiotic agents
is pivotal.1 Antimicrobial stewardship programmes (ASPs) have
been designed to measure and improve the appropriateness of
antibiotic use while minimizing the unintended consequences
of antibiotic use.2–8 As not every hospital or ward needs the
same level of improvement, ASP improvement strategies
should be tailored to local settings.9–11
One cornerstone of ASPs is the systematic measurement of the
(appropriateness of) local use to guide tailored improvement strat-
egies.12 Feedback is an important ingredient of such strategies, as
it further increases the effect of enabling strategies.13 Various
methods have been recommended to measure and feed-back on
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antibiotic use in hospitals, ranging from monitoring quantitative
antibiotic use at an institutional level, to performing point
prevalence studies (PPS) on the appropriateness of antibiotic
use in individual patients. However, efforts to perform these
methods, and information obtained with them, vary substan-
tially. For stewardship teams to optimally improve local anti-
biotic use, the comparative effectiveness of these various
options in measuring and feeding back data on antibiotic use
should be evaluated.13
In this cluster-randomized multicentre trial, we compared the
effects on length of hospital stay and secondary patient outcomes
of three recommended methods to measure and feed-back infor-
mation on hospital antibiotic use, when used as a first step of a
stewardship intervention to improve hospital antibiotic use.
Methods
Study design, setting and population
We performed a multicentre, cluster-randomized trial with repeated before
and after measurements in 21 Dutch hospitals to compare the effects of
three different methods to measure and feed-back information on hospital
antibiotic use (Figure 1). The methods were: (1) extraction of, and feedback
on, last year’s quantity of hospital pharmacy antibiotic use data (OVERALL
USE)14; (2) performance of a PPS to provide feedback on validated quality
indicators (QIs) for appropriate antibiotic use (PPS-QI, Table S1, available as
Supplementary data at JAC Online)15; and (3) performance of a PPS to pro-
vide feedback on a simplified, non-validated set of indicators (PPS-ECDC,
Figure S1).16 Measurements and feedback (phase 1) were followed by sys-
tematic development (phase 2) and performance (phase 3) of setting-
specific improvement strategies (Figure 1 and Box S1). Twenty-one Dutch












egen user on 22 July 2021
hospitals participated in the study. In each participating hospital, two main
clusters were selected: a non-surgical cluster containing the ‘high antibiotic
use’ specialties internal medicine (including geriatric patients), gastroenter-
ology and pulmonology; and a surgical cluster containing the high use spe-
cialties surgery, urology and orthopaedics. This trial was registered with the
Dutch Trial Registry, number 5933 (http://www.trialregister.nl, where the
trial protocol is available).
Randomization
Using clusters as the unit of randomization, the 42 clusters (21 pairs) were
randomly allocated to one of the three methods, using SAS Proc Survey se-
lect software, version 9.4. In each hospital, each method was allocated to
no more than one cluster by consecutive random sampling (Table S2 and
Text S1).
The Medical Ethics Research Committee of the Academic Medical
Center confirmed that the Dutch Medical Research Involving Human
Subjects Acts (WMO) did not apply to this study and that an official approval
by the committee was not required (October 2014).
Intervention
The intervention period lasted from September 2015 to May 2017 and con-
sisted of three phases (Box S1).
In phase 1, each local stewardship team performed a one-time (quanti-
tative or qualitative) antibiotic use measurement for the surgical and for
the non-surgical cluster in their hospital, according to the randomly
assigned method (Box S2). Data were processed into a feedback report by
the research team: results were summarized for each hospital cluster
and benchmarked against similar clusters from other hospitals. Each
team received two feedback reports, one for the surgical and one for the
non-surgical cluster, with instructions to use these reports only for their
allocated cluster.
In phase 2, all 21 hospital stewardship teams were trained in applying
an implementation tool (Figure S2)9 that supported a structured approach
to stewardship, i.e. the systematic development of setting-specific stew-
ardship improvement strategies based on the feedback reports. The tool
systematically guides stewardship teams through the stepwise process of
identifying targets for improvement from the feedback reports; assessing
local barriers that hinder appropriate use; and developing an action plan
including improvement strategies to overcome these barriers. Stewardship
teams were supported by the study team (i.e. the study coordinator, one in-
fectious diseases specialist and one implementation specialist) in applying
this structured approach to stewardship.
In phase 3, once instructed, stewardship teams applied this approach to
locally perform the stewardship improvement strategies. All improvement
strategies were initiated and executed by the local stewardship teams, the
role of the study team was only to guide and advise on this.
Before and after measurements
To assess (per method) the impact of the three-phase stewardship inter-
vention, we included for each of the 42 clusters, 100 admitted patients
receiving antibiotic treatment at baseline (February–May 2015, 4 monthly
sets of 25 patients), and again 100 patients per cluster after the interven-
tion (February–May 2017). Consecutive patients were selected from a
hospital-generated list containing all patients from the participating
clusters receiving antibiotic treatment. Within each cluster, we aimed at a
balanced distribution of medical specialties. Further details on in/exclusion
criteria and data collection are provided in Text S2 and Figure S3.
Primary and secondary outcome measures
Length of stay (LOS) was used as primary outcome measure. We used LOS
as a surrogate marker of quality of antibiotic use, as previous studies found
an association between appropriate antibiotic use and LOS.3–5 LOS was
defined as the number of days between admission and discharge for
community-acquired infections. For hospital-acquired infections, LOS
was defined as the number of days between start of antibiotic treat-
ment and discharge. Day of admission and day of discharge counted as
one hospital day. Secondary outcome measures were total antibiotic
use, use of IV antibiotics and use of restricted antibiotics [expressed in
Days-Of-Therapy (DOT) per 100 admissions and DOT per 100 patient-
days; (Table S3], admission to and duration of ICU stay, and hospital
mortality. If patients were admitted and discharged from the ICU on
the same day, the duration of ICU stay was set at 0.5 days. If patients
were admitted to the ICU more than once during their hospital stay, ICU
days were summed.
Process evaluation
At the end of the intervention a process evaluation was performed, to be
able to explain potential differences in effect between the various
methods.17
We collected information on hospital (e.g. hospital size, type) and stew-
ardship team characteristics (e.g. presence of stewardship team, frequency
of team meetings). Stewardship teams were asked to provide information
on time investment for obtaining feedback data; actual use of the feedback
report and the implementation tool; and on local stewardship improve-
ment activities performed. Also, stewardship teams self-assessed the
effectiveness of each measurement and feedback method [6-point Likert
scale, ‘not effective’ (0) to ‘very effective’ (5)].
Statistical analyses and sample size
The effectiveness of the three-phase stewardship intervention was
expressed as a difference in the primary outcome (LOS) and secondary out-
comes (DOT, in-hospital mortality, ICU admission and duration) before and
after intervention, overall and for each of the three methods. Mixed linear
effect models were used to accommodate the hierarchical structure in the
data (patients nested within clusters nested within hospitals) and to adjust
for differences in case-mix between baseline and post-intervention meas-
urements and between hospitals. LOS and ICU LOS were log-transformed
due to non-normal distributions. Continuous outcomes (LOS, DOT and ICU
LOS) were analysed with linear mixed models (LMM). For dichotomous out-
comes (ICU admission and in-hospital mortality) we used generalized linear
mixed models (GLMM).
We adjusted LOS for the secular trend in LOS using national annual
reference data (estimated #0.1 patient-days/year), to ensure that a dif-
ference in LOS in the model was more likely to reflect a change due to
interventions.18 Analyses were performed according to the intention-
to-treat (ITT) approach (i.e. with clusters allocated to the method they
had been randomized to) and the ‘as-treated’ (AT) approach (i.e.
according to the methods they actually used). Further details are pro-
vided in Text S3, including the effects specified for the process evalu-
ation variables, i.e. hospital and stewardship team characteristics, and
performance (at cluster level) of the five steps of the implementation
tool (translated into a sum score of actual steps performed by the stew-
ardship teams).
All analyses were done using IBM SPSS Statistics, version 23.0.
Sample size calculation
We assumed a baseline LOS of 9 days (SD 6.2) and a within-cluster correl-
ation (ICC) of 0.20, based on results of previous studies on length of hospital
stay.4,5 We estimated that with 21 hospitals with 2 clusters each, 4%25
patients per cluster before and 4%25 patients per cluster after the inter-
vention would be needed for this study to have a power of approximately
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80% to demonstrate a reduction in geometric mean length of stay
of 0.8 days (#9%) with an alpha of 0.05. This results in a total sample size
(before and after intervention) of 8400 patients. For the power analysis we
used SAS version 9.3.
Results
Study design, setting and population
Three university hospitals, sixteen teaching hospitals and two non-
teaching hospitals participated. Hospital size ranged between 255
and 1350 beds (median: 630 beds). Primary and secondary out-
come measures were assessed in 8840 patients: 4245 before
(2125 surgical/2120 non-surgical patients), and 4195 after inter-
vention (2104 surgical/2091 non-surgical patients). Distribution of
specialties within the clusters was comparable before and after
intervention (Table S4). Baseline characteristics (per cluster) are
shown in Table 1 and Table S5. Linear mixed models corrected for
any before and after differences.
Overall effectiveness of the three-phase stewardship
intervention
Primary outcome measure
The geometric mean LOS was 9.5 days (95% CI 8.9–10.1, N = 4245
patients) at baseline versus 8.7 days (95% CI 8.1–9.2, N = 4195
patients) after intervention, while adjusting for dependencies with-
in clusters and potential confounders (Table 2). After adjusting for
secular trend, the estimated decrease in geometric mean LOS was
0.5 days: 9.5 days (95% CI 8.9–10.1, N = 4245 patients) at baseline
versus 9.0 days after intervention (95% CI 8.5–9.6); P < 0.001,
N = 4195 patients. Figure S4 graphically illustrates the decreasing
trend of LOS over time.
Secondary outcomes
DOT per 100 admissions decreased from 1320 (95% CI 1253–
1387, N = 4245 patients) at baseline to 1185 (95% CI 1119–1252,
N = 4195 patients) after the intervention (#10%; P < 0.001), while
DOT per 100 patient-days remained unchanged (Table 2). Similar
trends were found for days of IV antibiotic therapy. A larger de-
crease was found for restricted DOT per 100 admissions (#19%,
P < 0.001, N = 324 versus N = 285) and for restricted DOT per 100
patient-days (#13%, P = 0.11, N = 324 versus N = 285).
The percentage of patients admitted to the ICU was lower after
the intervention (4.8%, N = 201 patients) compared with at base-
line (5.9%, N = 251 patients). There was no difference in ICU LOS or
in-hospital mortality (Table 2). Results were comparable for surgi-
cal and non-surgical clusters.
Comparative effectiveness of the three measurement
methods
Details about the comparative effects of the three methods on the
primary and secondary outcome measures are presented in
Table 3 and Table S6.
ITT
No significant differences in effect on LOS were found between the
methods (Overall use versus PPS-QI P = 0.97, Overall use versus
PPS-ECDC P = 0.69). In the Overall use group LOS decreased from
9.5 days (95% CI 8.7–10.4) to 9.0 days (95% CI 8.6–9.4), P = 0.02; in
the PPS-QI group LOS decreased from 9.5 days (95% CI 7.7–11.6)
to 8.9 days (95% CI 8.2–9.8), P = 0.02; in the PPS-ECDC group LOS
decreased from 9.2 days (95% CI 7.5–11.3) to 8.9 days (95% CI
8.1–9.7), P = 0.09.





(N = 4195) P value
Sex, male 2217 (52) 2207 (53) 0.72
Age, mean (SD) 68.5 (16)a 68.6 (16) 0.87
Infection, community-acquired/hospital-acquired 2990 (70)/1255 (30) 2939 (70)/1256 (30) 0.71
Type of diagnosis
Respiratory tract infection 1099 (26) 1096 (26) 0.80
Urinary tract infection 806 (19) 873 (21) 0.04
Skin and soft tissue infection 556 (13) 542 (13) 0.81
Orthopaedic infection 252 (6) 270 (6) 0.34
Abdominal infection 786 (19) 799 (19) 0.53
Other infection 352 (8) 268 (6) 0.001
Two or more possible infections 335 (8) 328 (8) 0.90
Diagnosis unknown 59 (1) 19 (1) <0.001
Charlson Comorbidity Index, median (IQR) 1 (0–2) 1 (0–2) 0.01
Received antibiotics <30 days before start of treatment 1539 (36) 1574 (38) 0.23
Received also prophylactic antibiotics 747 (18) 827 (20) 0.01
Admitted from a nursing home 170 (4) 220 (5) 0.01
Numbers are n (%) unless otherwise indicated. Percentages were calculated with the denominator excluding missing cases.
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No significant differences in effect on DOT were found between
the methods, except that PPS-QI and PPS-ECDC showed a signifi-
cantly larger decrease on restricted DOT per 100 admissions
(P = 0.04 and P = 0.02).
AT
The Overall use feedback report was actually used by stewardship
teams to develop improvement strategies for only two clusters
(5%), the PPS-QI feedback report was used for fifteen clusters
(36%), and the PPS-ECDC feedback report was used for twelve clus-
ters (29%). Twenty-one percent of the feedback reports were used
for a non-allocated cluster, for instance because a feedback report
provided more constructive information to identify targets for ASP
improvement strategies (see Process evaluation section), or be-
cause an improvement strategy based on one feedback report
was executed hospital-wide. Thirteen clusters (31%) did not base
their improvement strategies on any feedback report, for example
if they were part of ongoing local stewardship activities.
The PPS-QI method (15 clusters) and PPS-ECDC method (12
clusters) showed a larger decrease in LOS (#0.6 days for both
methods) as opposed to the Overall use method (2 clusters) and
the ‘no feedback used’ group (13 clusters) (!0.1 days and
#0.2 days respectively). PPS-QI showed a significantly larger de-
crease in restricted DOT per 100 admissions compared with the
other methods (P = 0.03).
Process evaluation
Effect of hospital and stewardship team characteristics
Table S7 shows the effects on the outcome measures of hospital
factors, such as hospital type, number of beds, presence of resi-
dency programmes, and stewardship team factors, such as the
presence of an officially appointed stewardship team, frequency
of team meetings, and staff full-time equivalents dedicated to
the stewardship team. No strong or consistent associations were
found.
Team’s evaluation of the three methods (phase 1)
Stewardship teams scored the PPS-QI method as most effective
for stewardship (Table 4). Targets for improvement could be
easily identified from the feedback report. It provided specific infor-
mation on the appropriateness of current antibiotic use, e.g. by





(N = 4195) D (%) P value
Primary
LOS geometric mean (95% CI)a,c,d,e,f,g 9.5 (8.9–10.1) 8.7 (8.1–9.2) #0.8 (#8) <0.001
LOS geometric mean (95% CI)–with
adjustment for timea,c,d,e,f,g,j
9.5 (8.9–10.1) 9.0 (8.5–9.6) #0.5 (#5) <0.001
Secondary
Days of antibiotic therapy (DOT)
per 100 patient-days (95% CI)a,b,c,d,e,f,g,h,i 86 (81–90) 84 (80–89) #2 (#2) 0.20
per 100 admissions (95% CI)d,e,f,g,h 1320 (1253–1387) 1185 (1119–1252) #135 (#10) <0.001
Days of IV antibiotic therapy (DOT)
per 100 patient-days (95% CI)a,c,d,e,f,g,i 53 (49–58) 54 (49–58) !1 (!2) 0.58
per 100 admissions (95% CI)a,d,e,f,g,h,i 897 (841–952) 806 (751–862) #91 (#10) <0.001
Days of restricted antibiotic therapy (DOT)
per 100 patient-days (95% CI)d,e,f,h 8 (7–9) 7 (6–9) #1 (#13) 0.11
per 100 admissions (95% CI)d,e,f,g,h 178 (152–204) 144 (118–170) #34 (#19) <0.001
ICU admissionb,c,d,e,f,g,h,i 251 (5.9) 201 (4.8) #50 (#1) 0.02
ICU LOS, geometric mean (95% CI)f,g 1.9 (1.6–2.2) 1.9 (1.6–2.3) !0.03 (!2) 0.82
In-hospital mortalitya,c,d,e,f 137 (3.2) 142 (3.4) !5 (!0.2) 0.69
Numbers are n (%) unless otherwise indicated. There were no missing cases. LOS, length of hospital stay.






ecommunity versus hospital-acquired infection;
ftype of admission specialty;
gdischarge to a nursing home;
hantibiotics received 30 days prior to admission;
iantibiotic; prophylaxis;
jtime since first included patient.
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reporting the percentage of patients in whom blood cultures were
performed before start of antibiotic therapy.
The Overall use method received the lowest effectiveness
score. Stewardship teams used the Overall use feedback reports
for only two clusters. The main reason for this was that the inter-
pretation of data was difficult, requiring knowledge on data regis-
tration and extraction procedures, and resulted in extra analyses
or extra information extraction from electronic patient records.
Data collection for the PPS-QI method was the most time-
consuming, followed by the PPS-ECDC and Overall use method
(respectively 48.5 versus 19.5 versus 6.7 h per cluster).
Use of the stewardship implementation tool (phase 2)
The stewardship implementation tool was used for 36 of 42 clus-
ters (86%). Stewardship teams identified targets for improvement
from the feedback reports for 36 clusters (step 1 of the tool). For 25
clusters a barrier analysis was performed (step 2–3) and for 29
clusters an action plan was developed, containing local improve-
ment strategies (step 4–5). The mean time invested by steward-
ship teams in applying the improvement tool (for the identification
of improvement targets, performance of a barrier analysis and de-
velopment of an action plan) was 9.2 h per cluster.
More-consistent use of the stewardship implementation tool
resulted in a larger decrease in total DOT, IV DOT and restricted
DOT. A significantly larger decrease in DOT per 100 patient-days
was found for a sum score equal to 1 (P = 0.03) and equal to 2
(P = 0.04), a significantly larger decrease in restricted DOT per 100
admissions was found if the sum score equalled 2 (P = 0.02) (Figure
S5 and Table S8).
Stewardship activities initiated by the stewardship
teams (phase 3)
A total of 52 setting-specific improvement projects were per-
formed in 42 clusters, with a median of one project (range: 1–3)
per cluster: mainly IV-to-oral switch projects (43%), and projects
focusing on appropriate treatment for patients with pneumonia
(21%) or the appropriate use of restricted antibiotics (19%).
Figure S6 and Table S9 illustrate the improvement activities
initiated by stewardship teams during the intervention period,
with the different colours reflecting the ‘as treated’ measurement
and feedback methods on which these activities were based.
Discussion
This multicentre, cluster-randomized study showed that the
three-phase stewardship intervention was associated with a sig-
nificant reduction in LOS, in addition to the secular trend, without
affecting ICU admission or in-hospital mortality. Also, a significant
decrease in DOT per 100 admissions and no change in DOT per 100














(N = 4195) D (%) P valueb
ITT approachc
Method 1: Overall use 14/42 (33) 7/21 (33) 7/21 (33) 9.5 (8.7–10.4) 9.0 (8.6–9.4) #0.5 (#5) Ref
Method 2: PPS-QI 14/42 (33) 7/21 (33) 7/21 (33) 9.5 (7.7–11.6) 8.9 (8.2–9.8) #0.6 (#6) 0.97
Method 3: PPS-ECDC 14/42 (33) 7/21 (33) 7/21 (33) 9.2 (7.5–11.3) 8.9 (8.1–9.7) #0.3 (#3) 0.69
AT approachd
Method 1: Overall use 2/42 (5) 1/21 (5) 1/21 (5) 8.8 (6.3–12.6) 8.9 (7.5–10.6) !0.1 (!1) 0.59
Method 2: PPS-QI 15/42 (36) 8/21 (38) 7/21 (33) 9.9 (7.8–12.7) 9.3 (8.1–10.6) #0.6 (#6) 0.19
Method 3: PPS-ECDC 12/42 (29) 7/21 (33) 5/21 (24) 9.6 (7.5–12.3) 9.0 (7.9–10.2) #0.6 (#6) 0.22
Method 4: Other 13/42 (31) 5/21 (24) 8/21 (38) 9.2 (8.1–10.4) 9.0 (8.3–9.6) #0.2 (#2) Ref
Numbers are n/N (%) unless otherwise indicated. There were no missing cases. LOS, length of hospital stay. Ref indicates the reference category.
The model was evaluated at mean age = 68.6 years and mean baseline LOS = 7.0 days.
aAdjusted for: age; comorbidity; type of diagnosis; community versus hospital acquired infection; type of admission specialty; discharge to a nursing
home; time since first included patient.
bInteraction effect=the difference in effect on outcomes (after minus before) between the measurement method and the reference method.
cITT approach: measurement methods as allocated by randomization.
dAT approach: measurement methods as used by the stewardship teams.
Table 4. Effectiveness of the intervention components as reported by
the stewardship teams
How effective did you find the following
elements to structurally develop and
implement setting-specific stewardship




Feedback report Overall use 2.9 (1.7–4.5)
Feedback report PPS-QI 3.8 (2.0–5.0)
Feedback report PPS-ECDC 3.3 (1.0–5.0)
Implementation tool to improve
appropriate antibiotic use
3.0 (1.0–4.5)
Educational meeting 3.2 (1.0–5.0)
Visits of the study team 3.6 (2.3–5.0)
Guidance, advice and reminders by the
study team
3.4 (2.0–5.0)
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patient-days was found, suggesting an absolute decrease in total
hospital antibiotic use per patient. A decrease in the use of
restricted antibiotics contributed to this. No significant differences
in effect were found between the three measurement and feed-
back methods. The process evaluation showed, however, that
feedback on the quality of antibiotic use was used more often to
identify targets for ASP improvement strategies and was preferred
over feedback on the quantity of use. Moreover, consistent use of
the stewardship implementation tool resulted in a larger decrease
in total DOT, IV DOT and restricted DOT.
Although our results suggest no significant differences in effect
between the three methods, stewardship teams found the Overall
use method the least effective for stewardship purposes,14 where-
as the PPS-QI method was regarded to be the most effective for
stewardship purposes as targets for improvement could be easily
identified from the feedback report. However, data collection for
the PPS-QI method was substantially more time consuming com-
pared with the PPS-ECDC and the Overall use method. At present, a
PPS still requires manual data collection, which is time consuming
and labour intensive. Electronic data registration will facilitate
future measurements.
The challenge for stewardship teams lies in systematically
selecting improvement strategies useful for their clinical setting;
the assessment of local barriers should inform the choice of the
appropriate improvement strategy for their setting.11,17,19 Flottorp
et al.9 developed a comprehensive checklist built on 12 frame-
works and taxonomies, including all types of barriers that might
prevent improvement in clinical practice. We provided stewardship
teams with an implementation tool based on this checklist.9 Use
of this tool encouraged stewardship teams to systematically de-
velop improvement strategies, based on local barriers, and to
make a structured action plan, providing clear focus for the teams.
Consistent use of the tool seemed to increase the effectiveness of
the intervention. Using a structured approach to stewardship may
therefore be as important as using an optimal measurement and
feedback method.
LOS was preferred as a primary outcome in this study as previ-
ous studies had found a strong association between appropriate
antibiotic use (process measure) and LOS (outcome measure).3,4,5
The use of LOS has several advantages: it is easy to measure,
applies to all included patients, reflects recovery time of hospital-
ized patients and drives hospital costs. As the parameter can be
influenced by several factors and secular trends, we statistically
adjusted for confounders (e.g. age, comorbidity, type of diagnosis)
that have shown to potentially affect LOS. Also, we corrected for
the secular trend of LOS over time using national reference data.
In addition to the primary outcome LOS, we applied several sec-
ondary outcomes including process (DOT) as well as outcome
measures (mortality, ICU admission and ICU duration). In our opin-
ion, process measures can complement outcome measures as
they are able to identify specific targets for quality improvement.
Our study has several strengths. To our knowledge, this is
the first cluster-randomized multicentre study comparing the
effectiveness of three recommended methods to measure and
feed-back information on hospital antibiotic use, and assessing
the effectiveness of a structured approach to stewardship. This
study design is highly recommended.10,20,21 Also, we showed that
even in Dutch hospitals, where antibiotic use is already low
compared with other countries, antibiotic use can be decreased.22
The impact of our structured approach to stewardship could
therefore potentially be larger in countries with higher antibiotic
consumption. Finally, we used an implementation tool that has
been rigorously developed.9 The tool guides stewardship teams to
systematically develop and perform setting-specific improvement
strategies. This tool can be used in other hospitals.11
Our study has some limitations. First, the design based on two
clusters within each hospital was prone to contamination: stew-
ardship teams operated hospital-wide, received feedback reports
on two clusters, and consequently could use information from an
allocated cluster report to initiate improvement strategies in a
non-allocated cluster. However, in line with the implementation
tool, improvement strategies were to be adapted to the needs and
context of each cluster by a systematic analysis of local barriers in
the clusters. Second, the initial study design did not include a con-
trol group, as we were merely interested in comparing the three
methods. In that respect we followed the conclusion of Ivers
et al.23 in their Cochrane review that ‘Future studies of audit and
feedback should directly compare different ways of providing
feedback.’ However, there was a significant number of clusters for
which no feedback report was used (AT approach), which can be
regarded as a control group, showing no significant decrease in
LOS. Also, we did correct for the secular trend of LOS over time
using national reference data.18 Third, hospitals with a higher
baseline LOS seemed to have more potential to reduce LOS (floor
effect). Even though we aimed to correct for this effect in our
model, it suggests that in hospitals with relatively low baseline
LOS, further stewardship strategies might have no measurable
return on investment: this remains to be established.
In conclusion, this multicentre cluster-randomized study
suggests that using data on the quality of antibiotic use is more
valuable than using data on the quantity of use to develop setting-
specific ASP improvement interventions. Moreover, we strongly
encourage stewardship teams to use a structured approach, as
for example supported by the implementation tool, to develop
their stewardship improvement strategies. Future studies should
consider focusing on obtaining appropriate data from existing
electronic health record systems, in order to obtain data for stew-
ardship purposes in a timely and efficient fashion.
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